FDA Grants Approval to New Treatment for Acute Myeloid Leukemia

FDA Grants Approval to New Treatment for Acute Myeloid Leukemia

Randomized clinical trial showed significant improvement in overall survival with glasdegib.

Azacytidine, Nivolumab Combination Provides Safe, Effective Balance in Relapsed/Refractory AML

Azacytidine, Nivolumab Combination Provides Safe, Effective Balance in Relapsed/Refractory AML

Researchers investigated the safety and efficacy of combination therapy with azacytidine and nivolumab for relapsed/refractory AML.

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.

Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study

Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study

A prospective cohort study from Denmark investigated the link between maternal hormonal contraception use before — more than 3 months and within 3 months — and during pregnancy and risk of leukemia in their children.

Risk of Relapse Up for Young Adults With Leukemia

Risk of Relapse Up for Young Adults With Leukemia

Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22-directed cytotoxin, has been approved for adult patients who have had at least two prior therapies for the disease.

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

A Novel Formulation of Melphalan May Not Prevent Complications Post-ASCT in Multiple Myeloma

A Novel Formulation of Melphalan May Not Prevent Complications Post-ASCT in Multiple Myeloma

High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Lorazepam Did Not Improve CINV in Pediatric Acute Lymphoblastic Leukemia

Lorazepam Did Not Improve CINV in Pediatric Acute Lymphoblastic Leukemia

A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.

No Negative Effects on HRQOL With Post-ASCT Maintenance Therapy for Multiple Myeloma

No Negative Effects on HRQOL With Post-ASCT Maintenance Therapy for Multiple Myeloma

Analysis of a cohort of patients with newly diagnosed multiple myeloma focused on the effect of post-ASCT maintenance therapy on health-related QOL and clinical outcomes.

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.

De-Escalation or Stoppage May Be Effective After Response to TKI Therapy in CML

De-Escalation or Stoppage May Be Effective After Response to TKI Therapy in CML

De-escalation of TKI therapy may be an effective management strategy among patients with CML who have responded to therapy.

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

A retrospective study sought to evaluate outcomes for patients with CLL who were treated with FCR, a highly effective treatment, and initially had refractory disease, experienced relapse early, or were unable to complete therapy due to toxicity.

Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events

Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events

In this study, researchers assigned 75 patients with newly diagnosed Philadelphia chromosome (Ph)-positive CML-CP to receive dasatinib 50 mg once daily.

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

[OncoTargets and Therapy] In a review of cancer stem cells (CSCs)/ovarian cancer stem cells (OCSCs), researchers discuss the implications of immunotherapy development based on studying cancer evolution by CSCs, and targeting OCSC surface markers to develop CAR-T immunotherapy.

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

An assessment of more than 71,000 patients with leukemia demonstrated the difference in outcomes for patients admitted to hospital on the weekend vs weekday. Findings were presented at the 2018 ASCO Annual Meeting.

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

Teaming up with multiple specialists to create an algorithm for managing AML in older patients improved clinician knowledge as well as provided patient-centered care, a presentation at 2018 ONS Annual Congress has shown.

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

Accelerated approval was granted by the FDA based on the results of a single-arm trial.

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

Slight changes in taste perceptions are noted in patients undergoing HSCT for hematologic cancers. In this study, researchers sought to determine how these changes affect quality of life and nutritional intake.

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

Inotuzumab ozogamicin (InO) use may have quality of life benefits for patients with R/R B-cell ALL, as well as producing improved clinical outcomes.

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

Some patients with chronic myeloid leukemia in chronic phase maintained TFR after receiving nilotinib, according to data from the ENESTfreedom study.

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.

Monitoring Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax

Monitoring Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax

What are key monitoring guidelines for patients with CLL being treated with venetoclax?

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib

1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing []

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.

Advanced Age Should Not Prohibit ASCT for Lymphoma

Advanced Age Should Not Prohibit ASCT for Lymphoma

As supportive care improves, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.

Imatinib an Effective Front-line Therapy for Patients With Pediatric CML

Imatinib an Effective Front-line Therapy for Patients With Pediatric CML

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.

More Communication, Support Needed to Manage Symptom Burden in CML

More Communication, Support Needed to Manage Symptom Burden in CML

Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

What is the concern behind PARP inhibitors and leukemia?

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

Comparison study via questionnaires assessed patients' and oncologists' views on likelihood of dying as a result of treatment shortly after beginning intensive or nonintensive chemotherapy for AML, and their views on prognosis 1 month later.

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.

Complications and Management of Coagulation Disorders in Leukemia Patients

Complications and Management of Coagulation Disorders in Leukemia Patients

[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

For adults with relapsed or refractory AML who have an IDH2 genetic mutation

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Hospice services and effective health care strategies are underutilized by patients with AML leading to suboptimal end-of-life care.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.

Stem Cell Transplant Patients Benefit From Inpatient Palliative Care

Stem Cell Transplant Patients Benefit From Inpatient Palliative Care

Palliative care added to transplant care improved relief from depression and PTSD symptoms following hematopoietic stem cell transplantation.

Guideline-driven Initiative Improves Pneumococcal Vaccination Rates Among aHSCT Recipients

Guideline-driven Initiative Improves Pneumococcal Vaccination Rates Among aHSCT Recipients

A nurse-led team developed a tracking tool that created a vaccination schedule from transplant date forward for autologous hematopoietic stem cell transplant recipients.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.

Blinatumomab Increased Overall Survival in B-cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab Increased Overall Survival in B-cell Precursor Acute Lymphoblastic Leukemia

Results from the TOWER trial demonstrate that blinatumomab (Blincyto) effectively improved OS in high-risk B-cell precursor ALL.

Letermovir Reduces CMV Infection, Improves Survival After Stem Cell Transplantation

Letermovir Reduces CMV Infection, Improves Survival After Stem Cell Transplantation

A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

The site of cancer care may partially explain survival differences between children and AYAs with ALL.

CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases

CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases

Genome editing technology illustrates progression of normal blood cells to leukemia.

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

Three specific genetic alterations may help identify pediatric patients with AMKL at high risk who may benefit from allogeneic stem cell transplants.

Blood-Forming Stem Cell Transplants (Fact Sheet)

Blood-Forming Stem Cell Transplants (Fact Sheet)

This fact sheet reviews bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) as they relate to the cancer treatment.

Arsenic and APL: Review of Therapy for an Acute Leukemia

Arsenic and APL: Review of Therapy for an Acute Leukemia

I was surprised to see an order for arsenic recently. What is this being used for?

Pretransplant Depression Associated With Worse Overall Survival

Pretransplant Depression Associated With Worse Overall Survival

An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.

Nilotinib for CML Associated With Improved Quality of Life

Nilotinib for CML Associated With Improved Quality of Life

Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.

Adding Pioglitazone to Imatinib May Improve Response in CML

Adding Pioglitazone to Imatinib May Improve Response in CML

Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Prenatal Herpes Virus Infection May Increase Childhood Leukemia Risk

Prenatal Herpes Virus Infection May Increase Childhood Leukemia Risk

Study results indicate that herpetic cytomegalovirus infection prior to birth subjects the child to increased odds of developing pediatric acute lymphoblastic leukemia.

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs